medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (2)

Indolent non-Hodgkin's lymphomas and anti-CD20 therapy: a literature review

Calderín MJM, de Castro SN, Reynaldo FG

Language: Spanish
References: 35
Page: 1-17
PDF size: 378.89 Kb.


ABSTRACT

Introduction: Indolent non-Hodgkin's lymphomas are notable for the challenge they pose from a therapeutic point of view. The introduction of rituximab, a monoclonal antibody that binds to the CD20 antigen of the B-lymphocyte membrane, revolutionized treatments up to that time and opened the way for the development of other anti-CD20 monoclonal antibodies.
Objective: To describe the general characteristics of indolent non-Hodgkin's lymphomas and anti-CD20 monoclonal antibodies, as well as the role of anti-CD20 therapy in these diseases.
Methods: A review of the literature published in the last 20 years, available in the repositories: Scielo, Scopus, Pubmed/Medline, Science Direct and Mediagraphic, was performed. Thirty-five papers were used to prepare this manuscript, 80% of which corresponded to the last 5 years.
Conclusions: Strong scientific evidence, accumulated over the last two decades, supports the clinical use of anti-CD20 monoclonal antibodies in the treatment of indolent non-Hodgkin's lymphomas. The effective use of these drugs as single agents or in combination with chemotherapy demonstrates their therapeutic versatility.


REFERENCES

  1. Pierpont TM, Limper CB, Richards KL. Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018;8:163. DOI: https://10.3389/fonc.2018.001631.

  2. Hilal T, Leis JF, Reeder CB. Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma. JAMA Oncol. 2018;4(6):859-60. DOI: https://10.1001/jamaoncol.2018.01112.

  3. Malcolm TI, Hodson DJ, Macintyre EA, Turner SD. Challenging perspectives on the cellular origins of lymphoma. Open Biol. 2016;6(9):160232. DOI: https://10.1098/rsob.1602323.

  4. Ribeiro JS, Dos Santos UR, Jardim IS, Dos Santos JL, Silva JF. Expression profile of immunological and vascular mediators in an unusual case of paravertebral primary cutaneous non-Hodgkin lymphoma. Int J Dermatol Clin Res. 2020;6(1):19-21. DOI: https://10.17352/2455-8605.0000394.

  5. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298-310. DOI: https://10.1016/S0140-6736(16)32407-25.

  6. Sheikhpour R, Pourhosseini F, Neamatzadeh H, Karimi R. Immunophenotype evaluation of Non-Hodgkin's lymphomas. Med J Islam Repub Iran. 2017;31:121. DOI: https://10.14196/mjiri.31.1216.

  7. Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820-41. DOI: https://10.1080/21645515.2018.15086247.

  8. Pérez-Zúñiga JM, Aguilar-Andrade C, Álvarez-Vera JL, Augusto-Pacheco M, Báez-Islas PE, Bates-Martín RA, et al. Generalidades sobre linfomas. Rev Hematol Mex. 2018[acceso 22/05/2021];19(4):174-88. Disponible en: https://revistadehematologia.org.mx/descarga/1853/8.

  9. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378:1396-407. DOI: https://10.1056/NEJMoa18014459.

  10. Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16(10):634-52. DOI: https://10.1038/s41571-019-0225-110.

  11. Salam DSDA, Thit EE, Teoh SH, Tan SY, Peh SC, Cheah SC. C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases. J Cancer. 2020;11(1):190-8. DOI: https://10.7150/jca.3695411.

  12. Cogliatti S, Bargetzi M, Bertoni F, Hitz F, Lohri A, Mey U. Diagnosis and treatment of marginal zone lymphoma. Swiss Med Wkly. 2016;146:w14324. DOI: https://doi.org/10.4414/smw.2016.1432412.

  13. Quintanilla-Martinez L. The 2016 updated WHO classification of lymphoid neoplasias. Hematol Oncol. 2017;35(S1):37-45. DOI: https://doi.org/10.1002/hon.239913.

  14. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica 2020;105(6):1494-506. DOI: https://doi.org/10.3324/haematol.2019.24354314. .

  15. Rougé L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020;367(6483):1224-30. DOI: https://10.1126/science.aaz935615.

  16. Conner KP, Devanaboyina SC, Thomas VA, Rock DA. The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation. Pharmacol Ther. 2020;212:107574. DOI: https://10.1016/j.pharmthera.2020.10757416.

  17. Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS. Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy. Ann Pharmacother. 2019;53(4):357-63. DOI: https://10.1177/106002801880358717.

  18. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21(9):1746-51. DOI: https://10.1200/JCO.2003.09.02718.

  19. Hirt C, Hoster E, Unterhalt M, Hänel M, Prange-Krex G, Forstpointner R, et al. Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the OstdeutscheStudiengruppeHämatologie und Onkologie and the German Low-Grade Lymphoma Study Group. Hemasphere. 2021;5(7):e600. DOI: https://10.1097/HS9.000000000000060019.

  20. Kalpadakis C, Pangalis GA, Sachanas S, Tsirkinidis P, Kontopidou FN, Moschogiannis M, et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018;132(6):666-70. DOI: https://10.1182/blood-2018-02-83360820.

  21. Jiang B, Ke X, Zhang Q, Xu W, Su H, Huang J, et al. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study. Sci Rep. 2020;10:11676. DOI: https://doi.org/10.1038/s41598-020-68360-021.

  22. AlDallal SM. Ofatumumab - a valid treatment option for chronic lymphocytic leukemia patients. Ther Clin Risk Manag. 2017;13:905-7. DOI: https://10.2147/TCRM.S14002322.

  23. Barth MJ, Czuczman MS. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncol. 2013;9(12):1829-39. DOI: https://10.2217/fon.13.21923.

  24. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698-704. DOI: https://10.1182/blood-2011-09-37832324.

  25. Rosenbaum CA, Jung SH, Pitcher B, Bartlett NL, Smith SM, Hsi E, et al. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). Br J Haematol. 2019;185(1):53-64. DOI: https://10.1111/bjh.1576825.

  26. Kiesewetter B, Neuper O, Mayerhoefer ME, Dolak W, Lukas J, Simonitsch-Klupp I, et al. A pilot phase II study of ofatumumabmonotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. Hematol Oncol. 2018;36(1):49-55. DOI: https://10.1002/hon.245426.

  27. Struemper H, Sale M, Patel BR, Østergaard M, Österborg A, Wierda WG, et al. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J Clin Pharmacol. 2014;54(7):818-27. DOI: https://10.1002/jcph.26827.

  28. Grigg A, Dyer MJ, Díaz MG, Dreyling M, Rule S, Lei G, et al. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Haematologica. 2017;102(4):765-772. DOI: https://10.3324/haematol.2016.15227228.

  29. Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. AdvTher. 2017;34(2):324-56. DOI: https://10.1007/s12325-016-0451-129.

  30. Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2920-6. DOI: https://10.1200/JCO.2012.46.971830.

  31. Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N. Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL. CPT Pharmacometrics Syst Pharmacol. 2014;3(10):e144. DOI: https://10.1038/psp.2014.4231.

  32. Greenwald M, Tesser J, Sewell L. Biosimilars Have Arrived: Rituximab. Arthritis. 2018; 2018:3762864. DOI: https://10.1155/2018/376286432.

  33. Fernández Águila JD, García Vega Yd, Hernández Casaña P, Hernández Cruz C, Medina Rodríguez BA, Viada González CE. Seguridad y efecto del uso compasivo del anticuerpo monoclonal anti-CD20 CIMABior(r). Rev Cubana Hematol Inmunol Hemoter. 2017 [acceso 20/05/2021];33(4):Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/60433.

  34. Hernández C, Saumell Y, Fernández JD, Cepero K, Marín D, de la Torre AV. Safety and Preliminary Effect of the Anti-CD20 Monoclonal Antibody 1B8 in B Cell Non-Hodgkin's Lymphoma: Results of An Expanded Access Program. Int J Pharm Pharm Sci. 2019 [acceso 25/05/2021];14(4):1-17. Disponible en: http://ijppr.humanjournals.com/wp-content/uploads/2019/04/1.Hern%C3%A1ndez-C-Saumell-Y-Fern%C3%A1ndez-JD-Cepero-K-Mar%C3%ADn-D-de-la-Torre-AV-Alcalde-M-%C3%81lvarez-NP-Lorenzo-Luaces-P-Garc%C3%ADa-MA.pdf34.

  35. García-Vega Y, Hernández-Castañeda P, Fernández-Águila JD, Hernández-Padrón C, Hernández-Cruz C, Medina-Rodríguez BA, et al. Efecto y seguridad del AcM anti-CD20 (CIMABIORr(r)) en pacientes con LNH indolente refractario o recaída. Rev Cubana Hematol Inmunol Hemoter. 2017 [acceso 24/05/2021];33(S1): Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/67135.




2020     |     www.medigraphic.com